Northern Trust Corp Purchases 16,894 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX)

Northern Trust Corp lifted its position in shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) by 4.3% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 405,517 shares of the biotechnology company’s stock after acquiring an additional 16,894 shares during the quarter. Northern Trust Corp owned approximately 0.68% of Aldeyra Therapeutics worth $2,024,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Raymond James Financial Inc. bought a new position in shares of Aldeyra Therapeutics during the 4th quarter worth $3,628,000. SG Americas Securities LLC lifted its holdings in Aldeyra Therapeutics by 14.4% during the 4th quarter. SG Americas Securities LLC now owns 22,365 shares of the biotechnology company’s stock worth $112,000 after purchasing an additional 2,822 shares in the last quarter. Hsbc Holdings PLC purchased a new stake in Aldeyra Therapeutics during the 4th quarter worth about $52,000. AlphaCentric Advisors LLC purchased a new stake in Aldeyra Therapeutics during the 4th quarter worth about $234,000. Finally, Wells Fargo & Company MN lifted its holdings in Aldeyra Therapeutics by 1.9% during the 4th quarter. Wells Fargo & Company MN now owns 393,654 shares of the biotechnology company’s stock worth $1,964,000 after purchasing an additional 7,348 shares in the last quarter. Institutional investors own 59.71% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on ALDX. Wall Street Zen raised Aldeyra Therapeutics to a “sell” rating in a report on Wednesday, May 21st. HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of Aldeyra Therapeutics in a report on Monday, May 19th. Finally, BTIG Research dropped their price objective on Aldeyra Therapeutics from $11.00 to $9.00 and set a “buy” rating on the stock in a report on Monday, April 7th.

Aldeyra Therapeutics Stock Performance

NASDAQ:ALDX opened at $2.22 on Monday. The business’s 50-day moving average price is $3.12 and its two-hundred day moving average price is $4.62. Aldeyra Therapeutics, Inc has a twelve month low of $1.14 and a twelve month high of $7.20. The stock has a market cap of $132.97 million, a P/E ratio of -2.29 and a beta of 0.92. The company has a quick ratio of 6.80, a current ratio of 6.80 and a debt-to-equity ratio of 0.18.

Aldeyra Therapeutics (NASDAQ:ALDX) last released its quarterly earnings results on Wednesday, May 14th. The biotechnology company reported ($0.17) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.08. As a group, equities analysts predict that Aldeyra Therapeutics, Inc will post -0.92 EPS for the current fiscal year.

Insider Buying and Selling at Aldeyra Therapeutics

In related news, major shareholder Perceptive Advisors Llc sold 3,400,000 shares of the firm’s stock in a transaction dated Thursday, April 3rd. The stock was sold at an average price of $1.42, for a total transaction of $4,828,000.00. Following the transaction, the insider now directly owns 5,875,851 shares of the company’s stock, valued at approximately $8,343,708.42. This trade represents a 36.65% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 9.60% of the company’s stock.

Aldeyra Therapeutics Profile

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.